myocarditis |
Disease ID | 725 |
---|---|
Disease | myocarditis |
Manually Symptom | (Waiting for update.) |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:16) C0018801 | heart failure | 33 C0009450 | infection | 27 C0030193 | pain | 5 C0042769 | virus infection | 5 C0026691 | kawasaki disease | 5 C0018802 | congestive heart failure | 4 C0021079 | immunosuppression | 3 C0039231 | tachycardia | 3 C0021311 | infections | 3 C0085274 | parvovirus b19 | 2 C1959583 | myocardial failure | 2 C0040100 | thymoma | 2 C0151517 | complete heart block | 1 C0019158 | hepatitis | 1 C0018801 | cardiac insufficiency | 1 C0018802 | congestive cardiac failure | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:2) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
rs3775291 | 23962581 | 7098 | TLR3 | umls:C0027059 | BeFree | A polymorphism in TLR3, rs3775291 (Leu412Phe), has been associated with the increased susceptibility to enteroviral myocarditis, protection against tick-borne encephalitis virus and HIV-1 infection. | 0.003181358 | 2013 | TLR3 | 4 | 186082920 | C | T,G |
rs386586050 | 23962581 | 7098 | TLR3 | umls:C0027059 | BeFree | A polymorphism in TLR3, rs3775291 (Leu412Phe), has been associated with the increased susceptibility to enteroviral myocarditis, protection against tick-borne encephalitis virus and HIV-1 infection. | 0.003181358 | 2013 | NA | NA | NA | NA | NA |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:22) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0027059 | acetylcysteine | D000111 | 616-91-1 | myocarditis | MESH:D009205 | therapeutic | 9261645 | ||
C0027059 | amitriptyline | D000639 | 50-48-6 | myocarditis | MESH:D009205 | marker/mechanism | 12638679 | ||
C0027059 | amphetamine | D000661 | 300-62-9 | myocarditis | MESH:D009205 | marker/mechanism | 18791201 | ||
C0027059 | ampicillin | D000667 | 69-53-4 | myocarditis | MESH:D009205 | marker/mechanism | 7919560 | ||
C0027059 | carbamazepine | D002220 | 298-46-4 | myocarditis | MESH:D009205 | marker/mechanism | 20129423 | ||
C0027059 | cephalexin | D002506 | 15686-71-2 | myocarditis | MESH:D009205 | marker/mechanism | 17111287 | ||
C0027059 | clozapine | D003024 | 5786-21-0 | myocarditis | MESH:D009205 | marker/mechanism | 10584719 | ||
C0027059 | cyclophosphamide | D003520 | 50-18-0 | myocarditis | MESH:D009205 | marker/mechanism | 11041571 | ||
C0027059 | dapsone | D003622 | 80-08-0 | myocarditis | MESH:D009205 | marker/mechanism | 19583683 | ||
C0027059 | fluorouracil | D005472 | 51-21-8 | myocarditis | MESH:D009205 | marker/mechanism | 7954023 | ||
C0027059 | haloperidol | D006220 | 52-86-8 | myocarditis | MESH:D009205 | marker/mechanism | 17965989 | ||
C0027059 | ifosfamide | D007069 | 3778-73-2 | myocarditis | MESH:D009205 | marker/mechanism | 4833912 | ||
C0027059 | imipramine | D007099 | 50-49-7 | myocarditis | MESH:D009205 | marker/mechanism | 2760582 | ||
C0027059 | lindane | D001556 | 58-89-9 | myocarditis | MESH:D009205 | marker/mechanism | 1702244 | ||
C0027059 | metoprolol | D008790 | 37350-58-6 | myocarditis | MESH:D009205 | marker/mechanism | 17593350 | ||
C0027059 | phenytoin | D010672 | 57-41-0 | myocarditis | MESH:D009205 | marker/mechanism | 3421797 | ||
C0027059 | propylthiouracil | D011441 | 51-52-5 | myocarditis | MESH:D009205 | marker/mechanism | 9219172 | ||
C0027059 | ticlopidine | D013988 | 55142-85-3 | myocarditis | MESH:D009205 | marker/mechanism | 10533962 | ||
C0027059 | tretinoin | D014212 | 302-79-4 | myocarditis | MESH:D009205 | marker/mechanism | 15842672 | ||
C0027059 | vitamin e | D014810 | 1406-18-4 | myocarditis | MESH:D009205 | marker/mechanism | 1926593 | ||
C0027059 | vitamin e | D014810 | 1406-18-4 | myocarditis | MESH:D009205 | therapeutic | 12924018 | ||
C0027059 | zidovudine | D015215 | 30516-87-1 | myocarditis | MESH:D009205 | marker/mechanism | 1733387 |
FDA approved drug and dosage information(Total Drugs:6) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D009205 | retrovir | zidovudine | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | Yes |
MESH:D009205 | retrovir | zidovudine | 50MG/5ML | SYRUP;ORAL | Prescription | AA | Yes | Yes |
MESH:D009205 | retrovir | zidovudine | 10MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
MESH:D009205 | retrovir | zidovudine | 200MG | TABLET;ORAL | Discontinued | None | No | No |
MESH:D009205 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
MESH:D009205 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
FDA labeling changes(Total Drugs:6) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D009205 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
MESH:D009205 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
MESH:D009205 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
MESH:D009205 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
MESH:D009205 | 09/19/2008 | retrovir syrup, capsules and tablets | zidovudine | Used in combination with 18 other antiretroviral agents for the treatment of HIV-1 infection | Dosing and administration information provided to children 6 weeks to less than 18 years of age Macrocytosis was reported in the majority of pediatric patients receiving Retrovir 180 mg/m2 every 6 hours in open-label studies New dosing regimen | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
MESH:D009205 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |